Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Arthritis Res Ther ; 23(1): 143, 2021 05 19.
Artigo em Inglês | MEDLINE | ID: mdl-34011407

RESUMO

OBJECTIVE: To assess the efficacy and tolerance of tocilizumab (TCZ) in giant cell arteritis (GCA) patients over 80. METHOD: GCA patients over 80 years old from the French Study Group for Large Vessel Vasculitis register who received TCZ were analyzed. RESULTS: Twenty-one GCA patients (median age 84 [81-90] years old, including nine over 85) received TCZ for the following nonexclusive reasons: glucocorticoid (GC)-sparing effect in 14, relapsing disease in 8, disease severity in 4, and/or failure of another immunosuppressant in 4. TCZ was introduced with GCs at diagnosis in 6 patients and at 8 [3-37] months after GC initiation in 15 others. After a median delay of 8 [2-21] months post-TCZ introduction, 14 (67%) patients were able to definitively stop GCs, including 6 who were GC-dependent before TCZ. At the last follow-up (median 20 [3-48] months), 11 (52%) patients had definitively stopped TCZ, and 2 additional patients had stopped but relapsed and resumed TCZ. Seven (33%) patients experienced 11 adverse events: hypercholesterolemia in 4 patients; infections, i.e., pyelonephritis, bronchitis, and fatal septic shock associated with mesenteric infarction following planned surgery (GCs were stopped for 1 year and TCZ infusions for 2 months), respectively, in 3 patients; moderate thrombocytopenia and moderate neutropenia in 2 patients; and a 5-fold increase in transaminase levels in another that improved after TCZ dose reduction. CONCLUSION: TCZ remains a valuable GC-sparing option in the oldest GCA patients with an interesting risk-benefit ratio. Mild-to-moderate adverse events were observed in one-third of patients.


Assuntos
Arterite de Células Gigantes , Idoso de 80 Anos ou mais , Anticorpos Monoclonais Humanizados/efeitos adversos , Arterite de Células Gigantes/tratamento farmacológico , Humanos , Imunossupressores , Resultado do Tratamento
2.
Rev Med Interne ; 41(9): 622-627, 2020 Sep.
Artigo em Francês | MEDLINE | ID: mdl-32660858

RESUMO

INTRODUCTION: Cocaine use is associated with multiple complications, some of which can mimic systemic diseases, especially Antineutrophil Cytoplasmic Antibody (ANCA) associated vasculitis. We report a case of Cocaine Induced Midline Destructive Lesions (CIMDL) for which a diagnosis of granulomatosis with polyangiitis (GPA) was discussed. CASE REPORT: A 42-year-old male, cocaine consumer, was admitted in our department for a centrofacial destructive process. He had no extra ear, nose and throat (ENT) involvement. ANCA were positive with a perinuclear fluorescence pattern and an anti-Proteinase 3 specificity. Regarding this unusual immunologic pattern and in the absence of histological argument for a GPA, a diagnosis of CIMDL was made. CONCLUSION: CIMDL is a centrofacial destructive process due to intranasal cocaine use. It is frequently associated with the presence of p-ANCA with both anti-HNE and anti-PR3 specificity.


Assuntos
Transtornos Relacionados ao Uso de Cocaína/complicações , Granulomatose com Poliangiite/etiologia , Perfuração do Septo Nasal/etiologia , Adulto , Anticorpos Anticitoplasma de Neutrófilos/efeitos adversos , Anticorpos Anticitoplasma de Neutrófilos/sangue , Transtornos Relacionados ao Uso de Cocaína/diagnóstico , Diagnóstico Diferencial , Granuloma Letal da Linha Média/diagnóstico , Granuloma Letal da Linha Média/etiologia , Granulomatose com Poliangiite/diagnóstico , Humanos , Masculino , Perfuração do Septo Nasal/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA